Scancell Holdings OTCPK:SCNL.F 주식 보고서 Scancell Holdings plc
OTCPK:SCNL.F 주식 보고서
SCNL.F 주식 개요 임상 단계의 바이오 제약 회사인 Scancell Holdings plc는 암과 전염병 치료를 위한 새로운 면역 치료법과 백신을 발견하고 개발하는 데 주력하고 있습니다.
위험 분석 + 3 더 많은 위험
모든 위험 점검 보기 Scancell Holdings plc 경쟁사 가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Scancell Holdings 과거 주가 현재 주가 UK£0.21 52주 최고치 UK£0.23 52주 최저치 UK£0.13 베타 0.45 11개월 변경 0% 3개월 변경 사항 -8.14% 1년 변경 사항 n/a 33년 변화 -14.20% 5년 변화 168.13% IPO 이후 변화 -58.75%
최근 뉴스 및 업데이트 Scancell Holdings plc Announces CEO Changes
Scancell Holdings plc, Annual General Meeting, Oct 25, 2024 Oct 01
Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024 Sep 18 Scancell Holdings plc Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial
Scancell Holdings plc Announces That A Group of Medical Oncologists in the Field of Melanoma Treatment Reviewed and Strengthened Scancell's Plan for A Phase 2/3 Registration Study Following Completion of the Ongoing Scope Study Jul 24
Scancell Holdings plc Appoints Florian Reinaud to the Board Jul 10 더 많은 업데이트 보기 Scancell Holdings plc Announces CEO Changes
Scancell Holdings plc, Annual General Meeting, Oct 25, 2024 Oct 01
Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024 Sep 18 Scancell Holdings plc Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial
Scancell Holdings plc Announces That A Group of Medical Oncologists in the Field of Melanoma Treatment Reviewed and Strengthened Scancell's Plan for A Phase 2/3 Registration Study Following Completion of the Ongoing Scope Study Jul 24
Scancell Holdings plc Appoints Florian Reinaud to the Board Jul 10
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board Mar 15
Scancell Holdings plc Directorate and Executive Changes Changes Feb 05
Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 26
Scancell Holdings plc Announces Update on SCOPE Trial Jan 18 Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million. Dec 20
Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million. Dec 02
Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million. Dec 01
Scancell Holdings plc, Annual General Meeting, Nov 29, 2023 Nov 01
Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023 Oct 05
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free Sep 29
Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma Sep 20
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1 Sep 14
Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development Sep 08
Scancell Appoints Sath Nirmalananthan as CFO Aug 29
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1 Jul 12
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1 Jul 11
Scancell Holdings plc Announces Positive Response in Covidity Trial Feb 13
Scancell Holdings plc Announces Executive Changes Feb 01
Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023 Jan 18
Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify Nov 01
Scancell Holdings plc, Annual General Meeting, Nov 21, 2022 Oct 30
Scancell Holdings plc Announces Board Changes Oct 26
Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial Aug 17
Scancell Holdings plc to Produce TCB Antibodies Jun 23
Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial Jun 15
Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital Jun 13
Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment Apr 11
Scancell Holdings plc Announces Update on Covidity Clinical Trial Mar 29
Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa Jan 31
Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1 Aug 27
Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine Jun 22
Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK Feb 03 주주 수익률 SCNL.F US Biotechs US 마켓 7D 0% -1.3% 3.9% 1Y n/a 22.8% 33.2%
전체 주주 수익률 보기
수익률 대 산업: US Biotechs 산업에 대해 SCNL.F 의 성과를 판단하기에는 데이터가 부족합니다.
수익률 대 시장: US 시장에 대해 SCNL.F 의 성과를 판단하기에는 데이터가 부족합니다.
가격 변동성 Is SCNL.F's price volatile compared to industry and market? SCNL.F volatility SCNL.F Average Weekly Movement n/a Biotechs Industry Average Movement 9.7% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.4% 10% least volatile stocks in US Market 3.0%
안정적인 주가: SCNL.F 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: 지난 1년간 SCNL.F 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
회사 소개 임상 단계의 바이오 제약 회사인 Scancell Holdings plc는 암과 전염병 치료를 위한 새로운 면역 요법과 백신을 발견하고 개발하는 데 주력하고 있습니다. 제품 후보로는 전이성 흑색종 치료를 위한 임상 2상 단계에 있는 면역항체 암 백신인 SCIB1과 비소세포 폐암을 포함한 고형암 환자 치료를 위해 평가 중인 SCIB2/iSCIB2 백신이 있습니다. 또한 삼중음성 유방암, 흑색종, 난소암, 폐암, 췌장암 등 고형암 치료를 위해 임상 1상/2상 시험 중인 시트룰린화 펩타이드 백신인 Modi-1과 동종 시트룰린화 암 항원을 표적으로 하는 Modi-2를 개발 중입니다.
자세히 보기 Scancell Holdings plc 기본 사항 요약 Scancell Holdings 의 수익과 매출은 시가총액과 어떻게 비교하나요? SCNL.F 기본 통계 시가총액 US$165.85m 수익(TTM ) -US$7.47m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) SCNL.F 손익 계산서(TTM ) 수익 UK£0 수익 비용 UK£0 총 이익 UK£0 기타 비용 UK£5.86m 수익 -UK£5.86m
주당 순이익(EPS) -0.0063 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 -541.3%
SCNL.F 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
